Rollie Carlson CEO of ImmunExpress is doing presentations. Most of the points are the same as previous presentations. However, this discussion of making Septicyte Rapid part of the standard of sepsis care is new.
What would it take to make Septicyte Rapid the standard of care?
Our test is the first FDA-cleared diagnostic in the U.S. that can differentiate SIRS from sepsis. We’ve presented our clinical validation at various major medical conferences and have published these data in peer-reviewed publications, as well as been disseminating the unique value proposition of our new technological approach to diagnosing sepsis. We need to make this the standard of care through education and awareness in different hospital systems.
Here in the U.S., different hospitals triage patients using a variety of inclusionary and exclusionary tests and SeptiCyte® RAPID should be included in that bundle of evaluations because it cancan improve patient outcomes.
In the U.S., Medicare CMS measures and rates hospitals by their sepsis patient management. Even within a hospital system, there is huge variability in ratings, and being able to improve and standardize patient management across the system will be a great advantage.
Although the highest cost is, of course, the high mortality rate, the management of sepsis is a significant financial burden for hospitals. By improving sepsis management, hospitals can reduce the length of stay while also reducing the number of other administered therapies.
FL